Fast Track Designation was granted for BB-301 following U.S. Food and Drug Administration (FDA) review of positive interim clinical study results and proprietary Responder Analysis planned for use in ...

Creates Transitional Platform From Human to Agentic AI OperatorsDetroit, Michigan--(Newsfile Corp. - November 14, 2025) - ...